A tight link between dysregulations in mRNA decay mechanisms and cancer hallmarks is now clearly established. Notably, abnormal stabilization of transcripts encoding pro-tumoral cytokines, chemokines or proto-oncogenes occurs during tumor development and progression. My research aims at deciphering the mechanisms involved in such dysregulations and focus on 2 key players in the control of mRNA fate: the Tristetraprolin zinc finger proteins TTP/ZFP36 and Tis11b/ZFP36L1, and microRNAs. I am using an integrative approach combining cellular and molecular biology, preclinical models and translational/clinical studies. The research program runs along 3 complementary axes: 1) the study of the molecular mechanisms through which TTP proteins and microRNAs regulate mRNA decay in normal and cancer cells; 2) the search for alterations in mRNA stability regulators (TTP proteins and microRNAs) in adrenocortical cancer and their evaluation as potential diagnostic/prognostic biomarkers; 3) the development of preclinical anti-cancer therapies targeting mRNA stability regulators in adrenocortical cancer.
Riotton Pharmaceutical Award
Faculty of Medicine of Geneva
Geneva, Switzerland, 1997
Mara E. Lieberman Award
Endocrine Society
Toronto, Canada, 2000
Searle Young Investigator Award
Aldosterone Conference
Toronto, Canada 2000
Servier Pharmaceutical Award
Swiss Endocrine Society
Bern, Switzerland, 2002
National Research Program in Reproduction and Endocrinology
INSERM
Grenoble, France, 2007
National Program in Translational Research (Contrat Hospitalier de Recherche Translationnelle)
INSERM
Grenoble, France 2010-2013